(1.26%) 5 127.79 points
(1.18%) 38 676 points
(1.99%) 16 156 points
(-1.22%) $77.99
(5.65%) $2.15
(0.02%) $2 310.10
(-0.16%) $26.79
(0.37%) $966.20
(-0.35%) $0.929
(-1.07%) $10.87
(-0.11%) $0.797
(0.35%) $91.45
2 days till quarter result
(amc 2024-05-07)
Expected move: +/- 6.92%
@ $73.34
发出时间: 14 Feb 2024 @ 23:26
回报率: 0.76%
上一信号: Feb 13 - 22:30
上一信号:
回报率: -1.89 %
Live Chart Being Loaded With Signals
Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing or acquiring technologies that help pharmaceutical companies to discover and develop medicines worldwide...
Stats | |
---|---|
今日成交量 | 138 103 |
平均成交量 | 179 366 |
市值 | 1.33B |
EPS | $0 ( 2024-05-02 ) |
下一个收益日期 | ( $1.130 ) 2024-05-07 |
Last Dividend | $0.456 ( 2010-07-02 ) |
Next Dividend | $0 ( N/A ) |
P/E | 24.39 |
ATR14 | $0.102 (0.14%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-04-30 | Aryeh Jason | Buy | 2 406 | Common Stock |
2024-04-30 | Aryeh Jason | Sell | 2 406 | Non-Qualified Stock Option (right to buy) |
2024-04-24 | Kozarich John W | Buy | 2 893 | Common Stock |
2024-04-24 | Kozarich John W | Sell | 2 893 | Non-Qualified Stock Option (right to buy) |
2024-03-25 | Davis Todd C | Buy | 3 556 | Common Stock |
INSIDER POWER |
---|
77.05 |
Last 99 transactions |
Buy: 843 765 | Sell: 95 185 |
音量 相关性
Ligand Pharmaceuticals 相关性 - 货币/商品
Ligand Pharmaceuticals 财务报表
Annual | 2023 |
营收: | $131.31M |
毛利润: | $119.75M (91.20 %) |
EPS: | $3.02 |
FY | 2023 |
营收: | $131.31M |
毛利润: | $119.75M (91.20 %) |
EPS: | $3.02 |
FY | 2022 |
营收: | $196.25M |
毛利润: | $143.42M (73.08 %) |
EPS: | $-0.310 |
FY | 2021 |
营收: | $277.13M |
毛利润: | $214.96M (77.56 %) |
EPS: | $2.22 |
Financial Reports:
No articles found.
Ligand Pharmaceuticals Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
First Dividend | $9.36 | 2007-04-03 |
Last Dividend | $0.456 | 2010-07-02 |
Next Dividend | $0 | N/A |
Payout Date | 0000-00-00 | |
Next Payout Date | N/A | |
# dividends | 2 | -- |
Total Paid Out | $9.81 | -- |
Avg. Dividend % Per Year | 0.00% | -- |
Score | 1.65 | -- |
Div. Sustainability Score | 8.02 | |
Div.Growth Potential Score | 1.503 | |
Div. Directional Score | 4.76 | -- |
Year | Amount | Yield |
---|---|---|
2007 | $9.36 | 14.30% |
2008 | $0 | 0.00% |
2009 | $0 | 0.00% |
2010 | $0.456 | 3.50% |
2011 | $0 | 0.00% |
2012 | $0 | 0.00% |
2013 | $0 | 0.00% |
2014 | $0 | 0.00% |
2015 | $0 | 0.00% |
2016 | $0 | 0.00% |
2017 | $0 | 0.00% |
2018 | $0 | 0.00% |
2019 | $0 | 0.00% |
2020 | $0 | 0.00% |
2021 | $0 | 0.00% |
2022 | $0 | 0.00% |
2023 | $0 | 0.00% |
2024 | $0 | 0.00% |
The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In conclusion, a more vigilant stance is recommended given the company's tentative dividend landscape.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
SLVO | Dividend Royal | 2023-11-20 | Monthly | 12 | 10.77% | 8.50 |
QYLD | Dividend Royal | 2023-11-20 | Monthly | 11 | 7.50% | 8.50 |
PSEC | Dividend Royal | 2023-12-26 | Monthly | 21 | 7.04% | 8.50 |
GAIN | Dividend Royal | 2023-12-04 | Monthly | 20 | 8.19% | 8.50 |
GLDI | Dividend Royal | 2023-11-20 | Monthly | 12 | 7.15% | 8.50 |
OXLC | Dividend Royal | 2023-12-14 | Monthly | 14 | 10.00% | 8.50 |
OXSQ | Dividend Royal | 2023-12-14 | Monthly | 21 | 9.10% | 8.50 |
HRZN | Dividend King | 2023-12-18 | Monthly | 15 | 6.60% | 8.45 |
USOI | Dividend Royal | 2023-11-20 | Monthly | 8 | 16.70% | 8.28 |
PFLT | Dividend King | 2023-11-15 | Monthly | 14 | 6.50% | 8.27 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | 0.378 | 1.500 | 2.44 | 3.66 | [0 - 0.5] |
returnOnAssetsTTM | 0.0596 | 1.200 | 8.01 | 9.62 | [0 - 0.3] |
returnOnEquityTTM | 0.0742 | 1.500 | -0.287 | -0.431 | [0.1 - 1] |
payoutRatioTTM | 0 | -1.000 | 0 | 0 | [0 - 1] |
currentRatioTTM | 14.15 | 0.800 | 10.00 | 8.00 | [1 - 3] |
quickRatioTTM | 12.49 | 0.800 | 10.00 | 8.00 | [0.8 - 2.5] |
cashRatioTTM | 1.368 | 1.500 | 3.51 | 5.27 | [0.2 - 2] |
debtRatioTTM | 0.00740 | -1.500 | 9.88 | -10.00 | [0 - 0.6] |
interestCoverageTTM | 2.60 | 1.000 | -0.148 | -0.148 | [3 - 30] |
operatingCashFlowPerShareTTM | 2.84 | 2.00 | 9.05 | 10.00 | [0 - 30] |
freeCashFlowPerShareTTM | -0.245 | 2.00 | -0.122 | -0.245 | [0 - 20] |
debtEquityRatioTTM | 0.00880 | -1.500 | 9.96 | -10.00 | [0 - 2.5] |
grossProfitMarginTTM | 0.920 | 1.000 | 10.00 | 10.00 | [0.2 - 0.8] |
operatingProfitMarginTTM | 0.0666 | 1.000 | -0.669 | -0.669 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | 8.04 | 1.000 | 10.00 | 10.00 | [0.2 - 2] |
assetTurnoverTTM | 0.158 | 0.800 | -2.28 | -1.826 | [0.5 - 2] |
Total Score | 8.02 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | 26.00 | 1.000 | 7.47 | 0 | [1 - 100] |
returnOnEquityTTM | 0.0742 | 2.50 | -0.185 | -0.431 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | -0.245 | 2.00 | -0.0815 | -0.245 | [0 - 30] |
dividendYielPercentageTTM | 0 | 1.500 | 0 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | 2.84 | 2.00 | 9.05 | 10.00 | [0 - 30] |
payoutRatioTTM | 0 | 1.500 | 0 | 0 | [0 - 1] |
pegRatioTTM | 0.0124 | 1.500 | -3.25 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | 0.378 | 1.000 | 3.06 | 0 | [0.1 - 0.5] |
Total Score | 1.503 |
Ligand Pharmaceuticals
Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing or acquiring technologies that help pharmaceutical companies to discover and develop medicines worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Veklury for the treatment of moderate or severe COVID-19; Teriparatide injection product for osteoporosis; Vaxneuvance for the prevention of invasive disease caused by Streptococcus pneumoniae; and Pneumosil, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia among children. The company also offers Rylaze, a recombinant erwinia asparaginase for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and pediatric patients; and Nexterone, a captisol-enabled formulation of amiodarone; and Zulresso, a captisol-enabled formulation of brexanolone for the treatment of postpartum depression. In addition, it provides Noxafil-IV, a captisol-enabled formulation of posaconazole for IV use; Duavee for the treatment of postmenopausal osteoporosis; Aziyo portfolio of commercial pericardial repair and CanGaroo envelope extracellular matrix products; Exemptia for autoimmune diseases; Vivitra for breast cancer; Bryxta and Zybev for various indications; and Minnebro for the treatment of hypertension. The company's partners and licenses programs, which are in clinical development used for the treatment of cancer, seizure, diabetes, cardiovascular disease, muscle wasting, liver and kidney disease, and other diseases. Further, it sells Captisol materials. The company was incorporated in 1987 and is headquartered in Emeryville, California.
关于 实时信号
此页面上呈现的实时信号有助于确定何时购买或出售NA. 信号具有高达1分钟的延迟;与所有市场信号一样,存在误差或错误的可能性。
实时交易信号不是绝对的,getagraph.com 对基于这些信号采取的任何行动概不负责,如《使用条款》中所述。这些信号是基于广泛的技术分析指标。